Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.50 |
| ▸ | CDK1 | P06493 | 12/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14934987 | 0.82 | SYK (0.48) | SYKCDK1CDK5PDK2PDK4 | |
| SCHEMBL7988896 | 0.79 | HRH4 (0.52) | SYKCDK1CDK5PDK2CCNB1 | |
| SCHEMBL14890705 | 0.77 | SYK (0.44) | SYKCDK1PDK2PDK4CCNB1 | |
| SCHEMBL18013223 | 0.77 | HTR3E (0.47) | SYKCDK1PDK2PDK4CCNE1 | |
| SCHEMBL18176130 | 0.77 | PIM1 (0.50) | SYKCDK1PDK2PDK4CCNE1 | |
| SCHEMBL2412673 | 0.76 | SYK (0.45) | SYKPDK2PDK4CCNE1CDK2 | |
| SCHEMBL2637996 | 0.74 | SYK (0.47) | SYKCDK1PDK2PDK4CCNE1 | |
| SCHEMBL2638109 | 0.74 | SYK (0.47) | SYKCDK1PDK2PDK4CCNE1 | |
| SCHEMBL2637993 | 0.74 | SYK (0.47) | SYKCDK1PDK2PDK4CCNE1 | |
| SCHEMBL12411127 | 0.73 | HSD11B1 (0.44) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | SYK 3487/4885CDK1 923/4885CDK5 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.